continual production and sustained levels of IFNa. The objective of this study was to investigate lentiviral interferon-alpha (LV-IFNa) activity and LV-mediated gene delivery to the murine bladder.
INTRODUCTION AND OBJECTIVES: Genomic characterization of urothelial bladder cancer (UBC) may help to identify alterations associated with tumor stage, novel therapeutic targets and biomarkers to predict outcomes. In this study, we evaluated genomic alterations of NMIBC, MIBC and metastatic UBC to identify genomic drivers of tumor stage. We also evaluated genomic alterations association with patient outcomes and DNA Damage Repair (DDR) alterations to predict neoadjuvant chemotherapy response.
METHODS: 454 UBC patient tumors were sequenced using next generation sequencing assay. 264 tumors (123 NMIBC, 112 MIBC and 29 metastatic) were chemotherapy naive primary tumors.
RESULTS: Patients whose primary tumors harbored TP53, RB1, TP53/MDM2, and cell cycle pathway alterations more frequently presented with advanced disease whereas those with tumors containing FGFR3, and RTK/RAS/RAF pathway alterations commonly presented with NMIBC (all q<0.001). TP53, RB1, TP53/MDM2, and cell cycle pathway alterations were associated with worse overall (OS) and metastasis free survival (MFS) whereas FGFR3 alterations were associated with more favorable OS and MFS (all q<0.05). RTK/RAS/ RAF pathway alterations were associated with more favorable MFS (q¼0.01). MIBC with DDR wild type, DDR alterations of unknown significance and DDR deleterious alterations had pathologic downstaging rates of 37%, 48% and 81% with platinum-based neoadjuvant chemotherapy (p¼0.013). Patients with ERCC2 mutations had significantly higher pathologic downstaging with platinum-based neoadjuvant chemotherapy compared to patients without ERCC2 mutations (p¼0.025). MIBC with DDR alterations had better OS with neoadjuvant chemotherapy compared to MIBC without DDR alterations (p¼0.04). Of note, MIBC with and without DDR alterations have similar OS in the absence of neoadjuvant chemotherapy (p¼0.78).
CONCLUSIONS: TP53, RB1 and FGFR3 alterations as well as TP53/MDM2, cell cycle and RTK/RAS/RAF pathway alterations showed an association with tumor stage and patient outcomes. MIBC with DDR alterations had higher pathological downstaging and better OS compared to MIBC with DDR wild type with platinum-based neoadjuvant chemotherapy. In absence of neoadjuvant chemotherapy, MIBC with and without DDR alterations have similar patient outcomes.
Source of Funding:
The Cycle for Survival (DBS), the Ruth L. Kirschstein National Research Service Award T32CA082088 (SI), the Sloan Kettering Institute for Cancer Research Cancer Center Support Grant P30CA008748 and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology.
MP54-05 PLASTICITY IN THE BIOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER
INTRODUCTION AND OBJECTIVES: Almost two thirds of patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy after cisplatin-based neoadjuvant chemotherapy (NAC) have invasive disease. Biological alterations of these cisplatin-resistant tumors induced by NAC remain largely unstudied.
METHODS: Radical cystectomy (RC) samples were available for gene expression analysis from 133 patients treated with cisplatinbased NAC who had residual invasive disease, of whom 116 had matched pre-NAC samples. In addition, the tumor bed (non-neoplastic scar tissue) of 21 post-NAC RC specimens with complete pathologic response (i.e. pT0N0) was profiled. Unsupervised consensus clustering was performed and the clusters were investigated for their biological and clinical characteristics. H&E staining and immunohistochemistry Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e713
